machineMD

Bern, SwitzerlandFounded 201911–50 employeesmachinemd.com

machineMD is a medical technology company focused on improving how brain function is measured. It develops neuro-ophthalmology diagnostic tools that analyze eye and pupil movements to support the diagnosis and monitoring of neurological disorders.

Visit machinemd.com ↗

Founded: 2019
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

The announcement accompanied a partnership to combine machineMD’s neurodiagnostic capabilities with Topcon’s multimodal retinal imaging, bringing functional and retinal biomarkers together to support clinical decision-making and patient management. Earlier, on Oct 14, 2024, the company’s neos™ device received EU-MDR Class IIa certification, an important regulatory milestone for its non-invasive neurodiagnostic approach. In April 2024, machineMD and gaitQ secured a research grant to monitor Parkinson’s development in the UK and Switzerland. The company’s disclosed funding history also includes a CHF 3.2 million seed round announced on Sep 6, 2022, led by the Guido Fluri Foundation.

Market position

machineMD operates at the intersection of medical devices, neuroscience, artificial intelligence, and virtual reality, with a focused neuro-ophthalmology proposition. Its neos® device uses infrared eye tracking in a headset form factor to quantify eye movements, pupils, and visual fields, aiming to make measurements of brain function more objective and accessible than specialist-dependent manual assessment. A second described approach applies a commercial VR headset and custom software to measure strabismus angles. Its market position is supported by EU-MDR Class IIa certification for neos in October 2024 and a March 2025 partnership with Topcon Healthcare, which brings retinal imaging into the clinical workflow alongside machineMD’s neurodiagnostic measures. The company remains a private, early-stage specialist rather than an established scale vendor.

Growth & opportunities

machineMD’s growth has progressed from early grants and seed financing toward regulatory and strategic milestones. Its funding history includes a CHF 1.257 million grant in July 2021, a CHF 1.23 million convertible note and CHF 200,000 grant in December 2021, and a CHF 3.2 million seed round announced on Sep 6, 2022. A further grant was recorded in April 2024, while the March 2025 pre-Series A announcement named Topcon Healthcare as lead investor without disclosing the round amount. The March 2025 partnership also creates a product-integration path linking neurodiagnostics with retinal imaging. EU-MDR Class IIa certification for neos in October 2024 marks a separate inflection point, moving the device through a significant regulatory milestone. Hiring signals across 2025 and 2026 include requirements engineering, usability, principal machine learning, and clinical affairs roles, suggesting continued investment in product development and clinical execution; no layoffs are reported. The trajectory therefore reflects a shift from research-backed development toward regulated product and partnership execution, but revenue, deployment, and hiring totals remain unavailable.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes machineMD distinct

reccy insights

What makes machineMD distinct

01Specializes in neuro-ophthalmology, using eye and pupil movement analysis to assess brain function.
02Aims to enable more objective, faster, and earlier assessment of neurological disorders.
03Combines diagnostic measurement with a headset-based form factor and infrared eye tracking.
04Works with clinical and research partners, including a collaboration with Topcon Healthcare on retinal imaging integration.
05Brings medical device development, clinical research, regulatory affairs, and software engineering expertise together.

Technology & products2

Technology & products

neos®
A non-invasive medical device that automates and quantifies assessment of eye movements, pupils, and visual fields using infrared eye tracking in a headset form factor.
Automated Measurement of Strabismus Angles Using Virtual Reality Headset
A method using a commercial virtual reality headset and custom software to objectively measure strabismus angles, replacing manual clinical measurements.

neos® non-invasive diagnostic device
Infrared eye tracking in a headset form factor
Quantitative pupillometry
Automated eye-movement and visual-field assessment
VR-based ocular alignment and strabismus-angle measurement

Recent updates1

Launches, partnerships and team changes from press coverage

Mar 18, 2025Partnership
machineMD and Topcon Healthcare, Inc. announced a partnership to integrate machineMD’s neurodiagnostic capabilities with Topcon’s multimodal retinal imaging technologies, combining functional and retinal biomarkers to support clinical decision-making and patient management.
startupticker.ch

About machineMD

Products: neos®, Automated Measurement of Strabismus Angles Using Virtual Reality Headset
Leadership: Dominic Senn, CEOPhil Norris, Chief Commercial Officer
Focus areas: Neuro-ophthalmology, neurological diagnostics, medical technology, brain function measurement, pupillometry, ocular alignment, clinical research
Headquarters: Bern, Switzerland
Founded: 2019
Employees: 11–50
Patents granted: 5 (Crunchbase)
Trademarks: 2